Novartis to face PD1 competition for Mekinist and Tafinlar combo
This article was originally published in Scrip
Executive Summary
The $20bn Novartis-GSK mega deal has brought the Swiss firm new opportunities this week as the European Medicines Agency announced CHMP positive opinions for Tafinlar (dabrafenib) and Mekinist (trametinib) as well as Revoldade (eltrombopag). However, Datamonitor Healthcare believes that sales of the melanoma combo in unlikely to be transformational for the market or the company thanks to pricing pressures and competition from anti-PD1s.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.